A multicenter phase 3 trial of lobeline sulfate for smoking cessation
- PMID: 19663757
- DOI: 10.5993/ajhb.34.1.12
A multicenter phase 3 trial of lobeline sulfate for smoking cessation
Abstract
Objective: To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation.
Methods: A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes.
Results: Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid.
Conclusion: Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.
Similar articles
-
A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation.Addiction. 2000 Aug;95(8):1161-71. Addiction. 2000. PMID: 11092064 Clinical Trial.
-
Family support and employment as predictors of smoking cessation success: a randomized, double-blind, placebo-controlled trial of nicotine sublingual tablets in chinese smokers.Am J Drug Alcohol Abuse. 2009;35(3):183-8. doi: 10.1080/00952990902839794. Am J Drug Alcohol Abuse. 2009. PMID: 19462302 Clinical Trial.
-
Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support.Chest. 2006 Aug;130(2):334-42. doi: 10.1378/chest.130.2.334. Chest. 2006. PMID: 16899830 Clinical Trial.
-
Effects of the nicotine patch on performance during the first week of smoking cessation.Nicotine Tob Res. 2003 Apr;5(2):169-80. doi: 10.1080/1462220031000074873. Nicotine Tob Res. 2003. PMID: 12745489 Review.
-
Varenicline: a first-line treatment option for smoking cessation.Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Clin Ther. 2009. PMID: 19393839 Review.
Cited by
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats.Biochem Pharmacol. 2024 Oct;228:116189. doi: 10.1016/j.bcp.2024.116189. Epub 2024 Apr 3. Biochem Pharmacol. 2024. PMID: 38580165
-
Targeting MAPK14 by Lobeline Upregulates Slurp1-Mediated Inhibition of Alternative Activation of TAM and Retards Colorectal Cancer Growth.Adv Sci (Weinh). 2025 Mar;12(10):e2407900. doi: 10.1002/advs.202407900. Epub 2025 Jan 22. Adv Sci (Weinh). 2025. PMID: 39840525 Free PMC article.
-
Lobeline for smoking cessation.Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD000124. doi: 10.1002/14651858.CD000124.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336780 Free PMC article.
-
Current pharmacologic treatments for smoking cessation and new agents undergoing clinical trials.Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619875925. doi: 10.1177/1753466619875925. Ther Adv Respir Dis. 2019. PMID: 31533544 Free PMC article. Review.
-
New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.AAPS J. 2018 Feb 9;20(2):29. doi: 10.1208/s12248-018-0192-y. AAPS J. 2018. PMID: 29427069 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
